

Emego® Plus

Meclozine Hydrochloride + Pyridoxine Hydrochloride

Description

Emego® Plus is a combination of Meclozine Hydrochloride and Pyridoxine Hydrochloride. Meclozine Hydrochloride is a piperazine-derivative antihistamine that is used as an antiemetic. It has antiemetic, anticholinergic, antihistaminic properties. Pyridoxine Hydrochloride (Vitamin B6), either alone or combination has been used to prevent nausea and vomiting due to its antiemetic properties.

Mode of action

Meclozine exhibits its action by an effect on CNS, possibly by its ability to block muscarinic receptors in the brain. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. It reduces the sensitivity of the labyrinthine apparatus. The site and mechanism of action of Meclozine in controlling vertigo from various conditions have not been clearly defined. Pyridoxine (B6), either alone or combination has been used to prevent nausea and vomiting due to its antiemetic property.

Composition

Emego® Plus Tablet: Each film coated tablet contains Meclozine Hydrochloride BP 25 mg and Pyridoxine Hydrochloride BP 50 mg.

Indications with dosage and administration

Emego® Plus is indicated for prevention and symptomatic treatment of following indications-

Nausea & vomiting associated with:

- Morning sickness during pregnancy: One tablet at night before sleeping or as directed by the physician.
- Radiation sickness: 1-2 tablets two hour before radiotherapy.

Vertigo and dizziness associated with:

- Motion sickness: 1-2 tablets one hour before traveling.
- Benign positional vertigo (BPV): 1-2 tablets each 12 hours till the end of episode.
- Vestibular system diseases (e.g. Meniere's disease, and labyrinthitis): 1-2 tablets each 12 hours.

Contraindications

Meclozine Hydrochloride and Pyridoxine Hydrochloride are contraindicated in individuals who have shown a previous hypersensitivity to these ingredients.

Side effects

Drowsiness, dry mouth, urinary retention or rare occasions, blurred vision have been reported.

Use in Pregnancy and Lactation

Meclozine: Pregnancy Category B. **Pyridoxine:** Pregnancy Category A. Epidemiological studies with Meclozine and Pyridoxine in women experiencing nausea and vomiting of pregnancy have revealed no evidence of a teratogenic effect attributable to the drug. Although Meclozine may excrete into the milk, it causes no harm in nursing babies.

Precautions

Due to its potential anticholinergic action, patients with asthma, bronchitis, emphysema, enlarged prostate, glaucoma or urinary tract blockade should take Meclozine (like other antiemetics) with caution. Patients should avoid alcoholic beverages while taking this drug. Meclozine is not recommended in last 2 weeks of pregnancy due to retrorenal fibroplasias risk.

Drug interactions

There may be increased CNS depression when Meclozine & Pyridoxine is administered concurrently with other CNS depressants, including benzodiazepines, barbiturates, tricyclic antidepressants, opiate agonists, skeletal muscle relaxants, antihistamines, alcohol, tranquilizers. Meclozine can increase the absorption of digoxin by decreasing gastrointestinal motility. MAO inhibitors may prolong and intensify the anticholinergic effects of Meclozine.

Overdosage

Symptoms: Extreme excitability, seizures, drowsiness, temporary nerve damage, hallucinations. **Treatment:** Appropriate supportive and symptomatic treatment.

Storage

Store in a cool and dry place, protected from light.

Packaging

Emego® Plus Tablet: Each carton contains 10X5 tablets in blister pack.



Manufactured by
Opsonin Pharma Limited
Rupatali, Barishal, Bangladesh.
® Registered Trade Mark.

251-03